Longevity Services & Practice Library
Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 73–96 of 235
Integrated Prevention Model Targets Healthspan at Population Scale
MORROW's Singapore flagship demonstrates an integrated model for delivering preventive healthcare at scale—combining clinical oversight with nutrition, movement, recovery, and coaching under one facility. The 45,000 sq ft installation reflects a sector-wide shift from discovering new longevity interventions toward building the infrastructure and systems required to implement them consistently and affordably.
Longevity.Technology and AND Capital Ventures launch partnership
Longevity.Technology and AND Capital Ventures announced a strategic partnership integrating AI-enabled market intelligence with operator-led investment strategy to identify growth-stage opportunities in longevity and healthspan innovation. The collaboration addresses market fragmentation by consolidating biotech, financing, clinical pipeline and public market signals into a unified intelligence platform for institutional investors.
Agentis, Ultrahuman tie wearables to Longevity Quotient
Agentis Longevity and Ultrahuman have integrated continuous glucose monitoring and wearable biomarker data into a clinical scoring system (Longevity Quotient) designed to bridge the gap between real-time metabolic data and actionable preventive care. The partnership addresses low engagement in preventive health practices by making personalized, data-driven interventions accessible at scale.
Hong Kong to host APAC longevity summit 2026
The 2026 APAC Longevity Medicine International Summit in Hong Kong will convene 2,000 researchers, clinicians, and policymakers to address the translation gap between geroscience discovery and clinical implementation. The event signals a maturation of the longevity field from laboratory breakthroughs toward systematic deployment of interventions at scale.
Biopeak’s longevity care earns repeat investor support
Biopeak, India's longevity care platform, secured $2.7 million in follow-on funding, demonstrating investor confidence in its longitudinal health optimization model. The company has progressed from concept to clinical delivery, addressing a gap in preventive care infrastructure within India's healthcare system.
Formulation Precision Over Ingredients in Longevity
Sooo.me, a bootstrapped supplement company founded by mathematician Erika Paulė, positions formulation precision and dose efficacy as central to longevity optimization rather than ingredient novelty or marketing claims. The company's approach reflects a broader shift in the longevity sector toward systems-level thinking about aging and the recognition that supplement adherence depends on integrating functional ingredients into everyday habits rather than clinical protocols.
The Longevity Investor Network Looks Back at 2025
The Longevity Investor Network deployed over $1.2 million into longevity-focused startups in 2025, continuing its mission to connect early-stage companies in aging biology, regenerative medicine, and senotherapeutics with informed capital. Since 2020, LIN has invested in 23 companies across cellular reprogramming, diagnostics, neurodegeneration, and tissue engineering, demonstrating sustained institutional commitment to translating aging science into commercial solutions.
John Hancock introduces longevity readiness tool
John Hancock has launched a personalized longevity readiness assessment tool developed with MIT AgeLab that scores individuals across eight life domains—health, finance, care, housing, daily activities, community, life transitions, and social connection. The tool addresses a critical gap in longevity planning: most interventions focus on extending lifespan rather than preparing people psychologically, socially, and practically for the reality of extended years.
TMRW lands $7m to expand longevity clinics
TMRW, an Australian longevity platform, secured $7 million in seed funding to expand clinical services and deepen biological age assessment through epigenetic testing in partnership with TruDiagnostic. The company differentiates itself by analyzing approximately 1,700 biological data points and integrating clinical support alongside diagnostics, moving beyond dashboard-only models.
Hertility announced as Women’s Health Partner for Longevity Show
Hertility has been named Scientific Lead Partner for the Women's Health Summit at the 2026 Longevity Show, positioning female biology as a structural framework—not peripheral content—for longevity science. The partnership addresses a fundamental data gap: longevity research has been calibrated to male physiology, requiring sex-specific diagnostic infrastructure and longitudinal data to advance clinical outcomes.
Cellular reprogramming enters human trials as longevity funding matures
The longevity sector has matured from speculative hype to evidence-driven investment, with capital concentration, clinical pathways, and regulatory engagement now defining the landscape. The shift from aspirational claims to measurable outcomes reflects broader maturation in biotech funding patterns and signals accelerating convergence between cellular biology research and practical medical application.
Scaling Aging Interventions: XPRIZE Judges Beyond Lab Efficacy
XPRIZE Healthspan is evaluating twenty finalist therapeutics across diverse modalities—stem cell therapies, genetic interventions, mitochondrial approaches, and others—using standardized measures of muscle, cognitive, and immune function. The competition explicitly judges interventions not only on biological efficacy but on manufacturing feasibility, cost structure, and realistic scalability, recognizing that population-level impact depends on more than laboratory performance.
Longevity capital pauses to think at Davos
The longevity field is maturing from speculative narrative to operational infrastructure, with investors and policymakers converging on evidence-based translation rather than technological spectacle. The shift reflects recognition that sustainable healthspan gains require business models and regulatory frameworks designed for decades-long compounding, not short-term capital cycles.
Longitudinal Biomarkers: From Snapshots to Clinical Trajectories
Continuous biomarker monitoring through at-home diagnostics—rather than annual snapshots—reveals whether health parameters are drifting toward dysfunction over months or years. This shift from episodic testing to longitudinal data collection addresses a critical gap in preventive medicine: understanding trajectories of biological change, not isolated readings.
Are global brands and employers longevity-ready?
Organizations across sectors remain structurally unprepared for demographic longevity, with the over-50 population underserved despite controlling significant spending power and representing a $67 billion market opportunity by 2035. Strategic repositioning toward healthspan optimization—rather than youth-centric models—is becoming a competitive and commercial imperative.
Longevity market projected to hit $67 billion by 2035
The global longevity market is projected to grow from $27.61 billion in 2025 to $67.03 billion by 2035, driven by increased prevalence of age-related disease, adoption of preventive healthcare, and advances in regenerative medicine, genomics, and biomarker technologies. This expansion reflects a structural shift toward intervention before disease manifests.
Summer Consistency Programs Strengthen Wellness Adherence
Restore Hyper Wellness launched a summer challenge designed to reinforce consistent engagement with wellness services across its 200-studio network. The program incentivizes behavioral consistency through frequency-based rewards, addressing a known barrier to sustained health optimization: the difficulty of maintaining practice adherence during seasonal disruption.
Gut Microbiome Testing Paired With Unproven Longevity Compounds
Decode Age, a Bengaluru-based sequencing laboratory and supplement company, combines gut microbiome testing with the sale of compounds including NMN, resveratrol, spermidine, and alpha-ketoglutarate, marketed as bioage interventions. The startup has grown to ₹11.9 crore in annual revenue with recent institutional funding, though human efficacy data for these compounds remains limited.
Sex-Specific Biology Reshapes Longevity Medicine
Healthcare systems designed around male physiology as default have created parallel blind spots for both women and men, undermining the personalization claims central to longevity medicine. Addressing sex-specific biology, diagnostic gaps, and equitable access is foundational to advancing longevity outcomes across populations.
Wellness Must Adopt Evidence Standards to Meet Longevity Demand
The wellness industry must evolve from aspiration-based claims to evidence-informed practice as consumers increasingly demand measurable healthspan outcomes, biomarker transparency, and scientific rigor. This structural shift toward mainstream longevity science creates both opportunity and accountability for an industry historically adjacent to rather than embedded in clinical prevention.
Capital deployment shapes longevity medicine's path to clinic
The seventh Longevity Investors Conference convenes leading geroscientists, entrepreneurs, and institutional investors in Gstaad to examine which longevity therapies will attract capital and reach clinical deployment. The event reflects the sector's maturation from early-stage hypothesis generation toward translational execution and scaled healthcare integration.
Forever Healthy Releases AI4L 1.0 for Practical Longevity
Forever Healthy released AI4L 1.0, an open-source system using Audit-Driven Prompting to generate evidence-based reviews of longevity interventions with live citation verification and zero-tolerance quality gates. This addresses the scalability problem of evaluating a fragmented landscape of senolytic, metabolic, and peptide-based therapies where evidence is dispersed across journals and clinical trials.
Inside the race to build longevity-ready business models
Business models built on traditional three-stage life assumptions are becoming obsolete as longevity reshapes market demand across leisure, housing, beauty, and healthcare sectors. Organizations that embed healthspan optimization and address demographic health disparities position themselves to capture significant commercial opportunity while improving population health outcomes.
GPER Agonist Enters Rigorous Aging Validation Framework
LNS8801, a GPER-activating drug candidate from Linnaeus Therapeutics, has entered the National Institute on Aging's Interventions Testing Program—one of the most rigorous preclinical validation systems in longevity science. This milestone reflects a maturation in aging research: the field now prioritizes healthspan preservation alongside lifespan extension, moving beyond simple longevity metrics to functional capacity and disease resilience.